TAGline October 2023
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.
TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline
TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.
TAG Remarks Submitted to United Nation High-Level Meetings (UN HLMs), September 2023
TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member…
TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR
TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.
New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN
As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.
At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens
Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6x24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.
TAG Reaction to the Price of GeneXpert Tests
Following intense pressure from TB-affected communities and civil society, Danaher’s price reduction of Xpert tests for TB and resistance to rifampicin (MTB/RIF Ultra) from $9.98 to $7.97 is a significant step forward that will help increase access to a lifesaving TB test and support countries to make progress toward closing major gaps in TB diagnosis.
Far Off Track: Funding for TB Research, 2018 – 2022
United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to…
TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023
Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV, TB, and HCV.
Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.